JP2023519931A5 - - Google Patents
Info
- Publication number
- JP2023519931A5 JP2023519931A5 JP2022559338A JP2022559338A JP2023519931A5 JP 2023519931 A5 JP2023519931 A5 JP 2023519931A5 JP 2022559338 A JP2022559338 A JP 2022559338A JP 2022559338 A JP2022559338 A JP 2022559338A JP 2023519931 A5 JP2023519931 A5 JP 2023519931A5
- Authority
- JP
- Japan
- Prior art keywords
- subunit
- pp2a
- amino
- agent according
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003736P | 2020-04-01 | 2020-04-01 | |
| US63/003,736 | 2020-04-01 | ||
| PCT/US2021/025230 WO2021202780A2 (en) | 2020-04-01 | 2021-03-31 | Methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519931A JP2023519931A (ja) | 2023-05-15 |
| JP2023519931A5 true JP2023519931A5 (enExample) | 2024-04-19 |
Family
ID=77927411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559338A Pending JP2023519931A (ja) | 2020-04-01 | 2021-03-31 | 癌を治療するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230149415A1 (enExample) |
| EP (1) | EP4127722A4 (enExample) |
| JP (1) | JP2023519931A (enExample) |
| KR (1) | KR20230017167A (enExample) |
| CN (1) | CN115769077A (enExample) |
| AU (1) | AU2021249111A1 (enExample) |
| CA (1) | CA3173799A1 (enExample) |
| MX (1) | MX2022012181A (enExample) |
| WO (1) | WO2021202780A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240398799A1 (en) * | 2021-08-19 | 2024-12-05 | Engine Biosciences Pte. Ltd. | Compositions and methods for generating synthetic lethality in tumors |
| WO2023177356A2 (en) * | 2022-03-18 | 2023-09-21 | Engine Biosciences Pte. Ltd. | Compounds and method for pkmyt1 inhibition |
| KR20250136774A (ko) * | 2024-03-08 | 2025-09-16 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| WO2025215187A1 (en) | 2024-04-11 | 2025-10-16 | My-T Bio Limited | Therapeutic compounds and their use |
| WO2025215188A1 (en) | 2024-04-11 | 2025-10-16 | My-T Bio Limited | Therapeutic compounds and their use as inhibitors of pkmyt1 |
| WO2025242880A1 (en) | 2024-05-24 | 2025-11-27 | My-T Bio Limited | Therapeutic compounds and their use |
| WO2026057597A1 (en) | 2024-09-10 | 2026-03-19 | My-T Bio Limited | Pkmyt1 inhibitors and their use |
| WO2026057598A1 (en) | 2024-09-10 | 2026-03-19 | My-T Bio Limited | Therapeutic compounds as pkmyt1 inhibitors and their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002607A1 (en) * | 2007-05-01 | 2008-12-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
| RS56680B1 (sr) * | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| EP3313819A1 (en) * | 2015-06-23 | 2018-05-02 | Case Western Reserve University | Compositions and methods for treating cancer |
-
2021
- 2021-03-31 CA CA3173799A patent/CA3173799A1/en active Pending
- 2021-03-31 MX MX2022012181A patent/MX2022012181A/es unknown
- 2021-03-31 WO PCT/US2021/025230 patent/WO2021202780A2/en not_active Ceased
- 2021-03-31 EP EP21780417.8A patent/EP4127722A4/en active Pending
- 2021-03-31 JP JP2022559338A patent/JP2023519931A/ja active Pending
- 2021-03-31 CN CN202180039991.2A patent/CN115769077A/zh active Pending
- 2021-03-31 KR KR1020227036696A patent/KR20230017167A/ko active Pending
- 2021-03-31 AU AU2021249111A patent/AU2021249111A1/en active Pending
-
2022
- 2022-09-28 US US17/936,089 patent/US20230149415A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519931A5 (enExample) | ||
| Maira et al. | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | |
| Baillache et al. | Recent developments in anticancer kinase inhibitors based on the pyrazolo [3, 4-d] pyrimidine scaffold | |
| Apsel et al. | Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases | |
| US11701353B2 (en) | Methods, compositions, and uses of novel FYN kinase inhibitors | |
| Ihle et al. | Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | |
| Chang et al. | Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→ methionine790 mutant | |
| J Shuttleworth et al. | Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors | |
| Gupta et al. | Medical management of meningioma in the era of precision medicine | |
| EP4045047A1 (en) | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers | |
| WO2021126816A1 (en) | Dosing regimen of a kras g12c inhibitor | |
| Wang et al. | Synthesis and biological activity of 6-substituted pyrrolo [2, 3-d] pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier | |
| KR20100055423A (ko) | Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체 | |
| CA2406278A1 (en) | Inhibitors of human phosphatidyl-inositol 3-kinase delta | |
| Patel et al. | 2, 4, 6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors | |
| AU2004312049A1 (en) | Treatment of malignant gliomas with TFG-beta inhibitors | |
| CN105611933A (zh) | 抗增生性化合物 | |
| EA035391B1 (ru) | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы | |
| Gustin et al. | The PIK3CA gene as a mutated target for cancer therapy | |
| Kong et al. | In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA | |
| US20160303137A1 (en) | Dual pi3k and wnt pathway inhibition as a treatment for cancer | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| EP3325100A1 (en) | Combination therapy using pdk1 and pi3k inhibitors | |
| Abdelhamed et al. | Pyrazolopyrimidines: a promising frontier in cancer treatment‐reviewing their potential as inhibitors of serine/threonine kinases | |
| Zhang et al. | Discovery and optimization of a series of novel morpholine-containing USP1 inhibitors |